IRVINE, Calif., Sept. 19 /PRNewswire-FirstCall/ -- Masimo Corporation , the inventor of Pulse CO-Oximetry and Read-Through Motion and Low Perfusion pulse oximetry, today announced its financial results for the quarter ended June 30, 2007, with product revenues of $47.6 million representing a 26% increase over $37.8 million for the second quarter of 2006. Including royalty revenues, Masimo reported total second quarter revenues of $63.7 million compared to $55.8 million for the second quarter of 2006. Net income for the quarter was $10.6 million, representing $0.13 GAAP or $0.19 non-GAAP earnings per common share.
Masimo also shipped a record 29,600 Masimo SET and Masimo Rainbow SET pulse oximeter units, excluding handheld pulse oximeters, during the second quarter of 2007, up from 23,700 in the comparable prior year period, resulting in an estimated worldwide installed base of 424,000 Masimo SET pulse oximeters.
For the quarter ended June 30, 2007, Masimo’s net income was $10.6 million compared to $13.9 million for the same quarter in 2006. These results reflect expected decreases in royalty revenue and interest income resulting from the January 2006 patent litigation settlement and related dividend distributions, as well as planned increases in research and development, sales, marketing and general and administrative expenses to support additional product development efforts and the Company’s global business expansion. Under the two class method for computing and reporting earnings per share, the Company reported second quarter 2007 net income attributable to common stockholders of $2.8 million or $0.13 per common share based on weighted average common shares outstanding of 20,732,014 as compared to $3.9 million or $0.19 per common share based on weighted average common shares outstanding of 20,301,629 for the second quarter 2006. For the quarter ended June 30, 2007, on a non-GAAP basis and adjusting only for the assumed conversion of preferred stock into common stock in connection with the Company’s recently completed initial public offering, net income was $0.19 per common share based on weighted average common shares outstanding of 55,344,517 as compared to $0.25 per common share based on weighted average common shares outstanding of 54,914,132 in the prior year period.
Joe E. Kiani, Chairman and Chief Executive Officer of Masimo, said, “We are happy to report a record second quarter with solid product revenue growth and net income that exceeded expectations. These results reflect the clinical community’s recognition of the benefits of our breakthrough read-through motion pulse oximetry, our strong customer service, and continued commitment to innovation, as evidenced by our new Rainbow SET platform.”
For the six month period ended June 30, 2007, Masimo’s product revenues were $93.4 million, up 29% from $72.5 million in the same prior year period. Including royalty revenues, Masimo’s total revenues were $122.6 million for the six month period ended June 30, 2007, up from $105.1 million in the prior year period. In the six month period ended June 30, 2007, Masimo shipped a record 56,200 Masimo SET and Masimo Rainbow SET pulse oximeter units, excluding handheld pulse oximeters, compared to 46,600 in the same prior year period.
Net income for the six month period ended June 30, 2007 was $19.7 million compared to $158.6 million in the comparable prior year period, which included $262.6 million in net patent litigation settlement proceeds and various one- time stock-based compensation charges related to dividend and bonus payments authorized in the first quarter of 2006. Under the two class method for computing and reporting earnings per share for the six month period ended June 30, 2007, Masimo reported net income attributable to common stockholders was $5.1 million, or $0.25 per common share based on weighted average common shares outstanding of 20,669,111, as compared to $2.67 per common share based on weighted average common shares outstanding of 19,975,936 for the six month period ended June 30, 2006. For the six- month period ended June 30, 2007, on a non-GAAP basis and adjusting only for the assumed conversion of preferred stock into common stock in connection with Masimo’s recently completed initial public offering, Masimo’s net income was $0.36 per common share based on total weighted average common shares of 55,311,614 as compared to $2.91 per share based on weighted average common shares outstanding of 54,588,439 in the prior year period.
Cash, cash equivalents and short-term investments were $35.0 million at June 30, 2007.
In August 2007, Masimo completed its initial public offering of 13,704,120 million common shares, comprised of 10,416,626 shares sold on behalf of selling stockholders and 3,287,494 shares sold on behalf of the Company, inclusive of the underwriters’ full exercise of its over-allotment option. The shares were sold at $17.00 per share, for net proceeds to the Company of approximately $47.0 million.
During the first six months of 2007, Masimo introduced a variety of new products including the new color Radical-7 and its latest measurement, Pleth Variability Index (PVI). The Radical-7 comes standard with the Rainbow SET MX circuit board which allows for upgrades to additional measurements through purchased software upgrades. PVI is a noninvasive measurement of functional hemodynamics, which clinicians have indicated may be valuable in monitoring fluid responsiveness and cardiac function. In the second quarter, Masimo also introduced its line of Rainbow single patient use adhesive sensors for adults, children, infants and neonates. The Rainbow sensors are capable of measuring not only oxygen saturation (SpO2), Pulse Rate and Perfusion Index, but also, carboxyhemoglobin (SpCO), methemoglobin (SpMet) and PVI. In June 2007, Masimo received U.S. Food & Drug Administration 510(k) clearance expanding its claims for SpMet monitoring to cover neonatal patients with its neonatal and infant Rainbow adhesive sensors. The ability to continuously and noninvasively measure methemoglobin levels in neonatal patients is especially important due to the use of inhaled nitric oxide (iNO) therapy to treat hypoxic respiratory failure in newborns, which has been shown to induce methemoglobinemia.
Financial Guidance
For the full year 2007, Masimo expects total revenues to be approximately $245 million and total product revenues to be approximately $195 million. The Company expects full year GAAP earnings per share to be approximately $0.43 and non-GAAP earnings per share, adjusted only for the assumed conversion of preferred stock into common stock in connection with Masimo’s recently completed initial public offering, to be approximately $0.55. The projections and guidance set forth above are estimates only and actual performance could differ.
Conference Call
Masimo will hold a conference call today at 2:00 p.m. PT (5:00 p.m. ET) to discuss the results. The dial-in numbers are (866) 700-7441 for domestic callers and (617) 213-8839 for international callers. The reservation number for both dial-in numbers is 11107851. A live Web cast of the conference call will be available online from the “investor relations” page of the Company’s corporate web site at www.masimo.com.
After the live web cast, the call will remain available on Masimo’s web site through October 19, 2007. In addition, a telephonic replay of the call will be available until October 3, 2007. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. Please use reservation code 65525346.
Non-GAAP Measures
Masimo prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP. In an effort to provide investors with additional information regarding the Company’s results and to provide a meaningful period-over-period comparison of the Company’s financial performance, the Company uses non-GAAP financial measures as defined by the Securities and Exchange Commission. The differences between the U.S. GAAP and non-GAAP financial measures are reconciled below. In presenting comparable results, the Company discloses non- GAAP financial measures when it believes such measures will be useful to investors, analysts and other interested parties in evaluating the Company’s underlying business performance on a comparable basis with past and future reported earnings per share and with the financial guidance provided within this press release. Management uses the non-GAAP financial measures to evaluate the Company’s financial performance against internal budgets and targets. Importantly, the Company believes non-GAAP financial measures should be considered in addition to, and not in lieu of, U.S. GAAP financial measures. These non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles. The Company’s non-GAAP financial measures may be different from non-GAAP financial measures used by other companies.
About Masimo
Masimo develops innovative monitoring technologies that significantly improve patient care-helping solve “unsolvable” problems. In 1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET, and with it virtually eliminated false alarms and increased pulse oximetry’s ability to detect life-threatening events. More than 100 independent and objective studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations. Our Masimo SET platform has significantly addressed many of the previous technology limitations, has substantially contributed to improved patient outcomes and has been referred to by several industry sources as the gold standard in pulse oximetry. In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of “Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications.” Additional information about Masimo and its products may be found at www.masimo.com.
Forward-Looking Statements
This press release includes forward-looking statements. All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements about: our plans, objectives, strategies and prospects regarding, among other things, the financial condition, results of operations and business of ours and our subsidiaries; our expectations regarding the value of monitoring methemoglobin levels in neonatal patients; the value of new measurements such as PVI; expectations regarding our ability to design and deliver innovative new noninvasive technologies and expand into additional areas of vital signs monitoring and measurements, including carbon monoxide, methemoglobin and PVI; and expectations for total revenues, product revenues, GAAP earnings per share and non-GAAP earnings per share for the full fiscal year 2007. These forward- looking statements are based on current expectations about future events affecting us and are subject to uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control including: risks related to our reliance on Masimo SET and related products for substantially all of our revenue; risks related to any failure in protecting our intellectual property; risks related to exposure to competitors’ assertions of intellectual property claims; risks related to the highly competitive nature of the markets in which we sell our products; risks related to the failure to continue developing innovative products; risks related to the introduction of competing products; risks related to the lack of acceptance of new products; risks related to the loss of our customers; risks related to increases in prices for raw materials or the loss of key supplier contracts; risks related to the failure to retain senior management or replace lost senior management; risks related to product liability claims exposure; risks related to the absence of expected returns from the amount of intangible assets we have recorded; the risk that our financial performance in the third and fourth quarters of 2007 may not meet expectations; risks and uncertainties related to the maintenance and strength of our brand; and other factors discussed in the “Risk Factors” section of our Prospectus dated August 7, 2007 filed with the Securities and Exchange Commission. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the risk factors contained in our Prospectus dated August 7, 2007, whether as a result of new information, future events or otherwise, except as may be required under the federal securities laws.
Masimo Corporation Investors: Mark P. de Raad Executive Vice President and Chief Financial Officer (949) 297-7080 mderaad@masimo.com Media: Tom McCall Vice President, Corporate Communications (949) 297-7075 tmccall@masimo.com
Masimo, SET, Signal Extraction Technology, Radical, Radical-7, Rad57, APOD, and Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Application, ARM, Acoustic Respiratory Monitoring, Rainbow, SpCO, SpMet, PVI, SpHb and Pulse CO-Oximeter are registered trademarks or trademarks of Masimo Corporation.
MASIMO CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share amounts) December 31, June 30, 2006 2007 (unaudited) ASSETS Current assets Cash and cash equivalents $55,382 $35,017 Accounts receivable, net of allowance for doubtful accounts 22,350 27,421 Royalties receivable 1,289 14,455 Inventories 17,135 22,591 Deferred tax assets 18,116 20,401 Other current assets 3,043 4,351 Total current assets 117,315 124,236 Deferred cost of goods sold 21,899 25,631 Property and equipment, net 10,290 10,917 Deferred tax assets 3,163 3,761 Restricted cash 507 508 Intangible assets, net 4,592 4,906 Goodwill 448 448 Other assets 859 3,678 Total assets $159,073 $174,085 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Accounts payable $10,142 $17,846 Accrued compensation 12,207 9,651 Accrued liabilities 4,655 9,203 Dividends payable 37,533 362 Income taxes payable 1,245 2,598 Deferred revenue 13,880 18,108 Current portion of long-term debt 7,528 12,046 Total current liabilities 87,190 69,814 Deferred revenue 490 744 Long-term debt, less current portion 13,514 25,007 Other liabilities 918 1,263 Total liabilities 102,112 96,828 Commitments and contingencies - - Stockholders’ equity Convertible preferred stock 88,328 92,241 Common stock 17 17 Treasury stock (628) (1,209) Accumulated other comprehensive loss (317) (625) Accumulated deficit (30,439) (13,167) Total stockholders’ equity 56,961 77,257 Total liabilities and stockholders’ equity $159,073 $174,085 MASIMO CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share information) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2006 2007 2006 2007 Revenue: Product $37,845 $47,627 $72,524 $93,391 Royalty and license fee 17,929 16,053 32,556 29,243 Total revenue 55,774 63,680 105,080 122,634 Cost of goods sold 14,956 17,919 31,094 34,820 Gross profit 40,818 45,761 73,986 87,814 Operating expenses: Research and development 3,143 5,460 14,937 10,914 Selling, general and administrative 15,066 21,577 51,181 42,979 Patent litigation expenses (proceeds) 64 - (262,601) - Antitrust litigation 49 465 73 475 Total operating expenses 18,322 27,502 (196,410) 54,368 Operating income 22,496 18,259 270,396 33,446 Non-operating income (expense): Interest income 1,979 189 4,638 544 Interest expense (471) (685) (976) (1,112) Other 88 170 187 211 Total non-operating income (expense) 1,596 (326) 3,849 (357) Income before provision for income taxes 24,092 17,933 274,245 33,089 Provision for income taxes 10,170 7,377 115,626 13,436 Net income 13,922 10,556 158,619 19,653 Preferred stock dividend - - (58,571) - Accretion of preferred stock (1,956) (1,956) (4,073) (3,913) Undistributed income attributable to preferred stockholders (8,102) (5,802) (42,584) (10,630) Net income attributable to common stockholders $3,864 $2,798 $53,391 $5,110 Net income per common share: Basic $0.23 $0.17 $3.33 $0.31 Diluted $0.19 $0.13 $2.67 $0.25 Weighted-average number of common shares: Basic 16,509,563 16,692,547 16,025,828 16,642,779 Diluted 20,301,629 20,732,014 19,975,936 20,699,111
The following table presents details of the stock-based compensation expense that is included in each functional line item in the condensed consolidated statement of operations above (in thousands):
Three Months Ended Six Months Ended June 30, June 30, 2006 2007 2006 2007 Cost of goods sold $ 75 $ 45 $ 1,966 $ 78 Research and development 35 164 8,418 275 Selling, general and administrative $ 194 $ 849 $21,428 $ 1,295 MASIMO CORPORATION Unaudited Reconciliation of GAAP to Non-GAAP Earnings per Share
The following tables provide a comparison of our earnings per share calculated under Emerging Issues Task Force Issue No. 03-6, “Participating Securities and the Two-Class Method under FASB Statement No. 128", or EITF 03- 6, in accordance with GAAP and the non-GAAP if converted method based upon Financial Accounting Standards Board No. 128 “Earnings per Share”, or FASB 128. The non-GAAP if converted method assumes conversion of all shares of the Company’s preferred stock into common stock as of December 31, 2006. As a result of the three-for-one forward stock split of our common stock effected on June 25, 2007, the conversion price of each outstanding share of our preferred stock was reduced to one-third of the pre-stock split conversion price, which effectively increased the conversion ratio to three shares of common stock for one share of preferred stock. Upon closing of our initial public offering on August 13, 2007, all outstanding shares of our preferred stock were converted into an aggregate of 34,612,503 shares of common stock. Therefore, effective August 13, 2007, the Company transitioned from computing earnings per share from the two class method, in accordance with EITF 03-6 to the if converted method in accordance with FASB 128. The Company believes that the following non-GAAP earnings per share information is relevant and useful information that can be used by analysts, investors and other interested parties to assess the Company’s performance on a comparable basis to future reported earnings per share. Accordingly, the Company is disclosing this information to permit additional analysis of the Company’s performance (in thousands, except share data):
Three Months Ended Six Months Ended June 30, June 30, 2006 2007 2006 2007 Numerator: GAAP net income $3,864 $2,798 $53,391 $5,110 Preferred stock dividend (1) - - 58,571 - Accretion of preferred stock (2) 1,956 1,956 4,073 3,913 Undistributed income attributable to preferred stockholder (3) 8,102 5,802 42,584 10,630 Non-GAAP net income 13,922 10,556 158,619 19,653 Denominator: GAAP Weighted average number of shares - Diluted 20,301,629 20,732,014 19,975,936 20,699,111 Weighted average preferred shares (4) 34,612,503 34,612,503 34,612,503 34,612,503 Non-GAAP Weighted average number of shares - Diluted 54,914,132 55,344,517 54,588,439 55,311,614 Earnings per share - Diluted: GAAP earnings per share $0.19 $0.13 $2.67 $0.25 Adjustments to if converted method 0.06 0.06 0.24 0.11 Non-GAAP earnings per share $0.25 $0.19 $2.91 $0.36 Adjustments: (1) Under the if converted method, no shares of preferred stock would have been outstanding, therefore no dividends would have been recorded specifically for preferred shareholders. (2) Under the if converted method, no shares of preferred stock would have been outstanding; therefore no allocation of undistributed income to preferred stockholders would have been made. (3) Under the if converted method, no shares of preferred stock would have been outstanding; therefore no accretion of preferred stock would have been recorded. (4) Under the if converted method, all shares of preferred stock would have been outstanding of the entire period.
Masimo Corporation
CONTACT: Investors, Mark P. de Raad, Executive Vice President and ChiefFinancial Officer, +1-949-297-7080, mderaad@masimo.com, or Media, TomMcCall, Vice President, Corporate Communications, +1-949-297-7075,tmccall@masimo.com, both of Masimo Corporation
Web site: http://www.masimo.com/
